Smart ECM
Account
RESAccademia Nazionale Di MedicinaEvento 486639 / Edizione 1

22Nd meet the professor. Advanced international breast cancer course (aibcc)

Convegno internazionale biennale a Padova sul carcinoma mammario: aggiornamento su sottotipi molecolari HR+/HER2-, HER2+ e TNBC, terapie neoadiuvanti e adiuvanti, malattia avanzata e hot topics su biopsia liquida, AI e oncofertilità.

Provider
Accademia Nazionale Di MedicinaAccademia Nazionale Di Medicina (31)
Crediti ECM
11
Costo
120,00 €
Durata
11 ore
Date
17 - 18 settembre 2026
Richiedi info iscrizione
Aggiungi al Piano

Razionale scientifico

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life. As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more. New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments. The 22nd AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Luogo

Palazzo della Salute
Via San Francesco, 90, Padova (PD)

Programma

Thursday, September 17
  • 10:30Introduction to the ConferencePierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
  • 10:45ESMO President Elect - Welcome RemarkGiuseppe Curigliano
  • 11:00SESSION I – HR+/HER2-: Clinical and biological definition of early and late risk of relapseCarmine De Angelis
  • 11:20Navigating adjuvant ET optionsStephen Johnston
  • 11:40Opportunities for radiation therapy de-escalationPhilip Poortmans
  • 12:00Exploiting endocrine resistance in advanced diseaseGaia Griguolo
  • 12:20Revisited metastatic algorithmPeter Fasching
  • 12:40Discussion
  • 13:20Lunch
  • 14:20SESSION II – HER2+: Turning biological heterogeneity into clinical actionAleix Prat
  • 14:40Treatment escalation: neoadjuvant vs post-neoadjuvant strategiesSibylle Loibl
  • 15:00Redefining 1st line for advanced disease: induction CT vs ADC? Duration? Which maintenance?Sandra Swain
  • 15:20Discussion
  • 15:40Clinical Multidisciplinary Shooting Session 1 – HR+/HER2- and HER2+Pierfranco Conte, Carmine De Angelis, Lucia Del Mastro, Hesham Ahmed Gaballah Elghazaly, Peter Fasching, Gaia Griguolo, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Philip Poortmans, Aleix Prat, Hope Rugo, Tanja Spanic, Sandra Swain
Friday, September 18
  • 09:00SESSION III – TNBC: Markers of sensitivity/resistance to immunotherapyMaria Vittoria Dieci
  • 09:20Balancing escalation and de-escalation in eTNBCHope Rugo
  • 09:401st line PD-L1+: ADC + ICI for all?Mario Giuliano
  • 10:00Discussion
  • 10:20Coffee break
  • 10:50SESSION IV – Round table: focus on young women – Fertility and pregnancyMatteo Lambertini
  • 10:50Hereditary syndromes including BRCA mutationsBanu Arun
  • 10:50Surgical managementEleftherios Mamounas
  • 12:00Discussion
  • 12:30Lunch
  • 13:30SESSION V – HOT TOPICS: Clinical implications of liquid biopsy: MRD, monitoring, guide for target treatmentLuca Malorni
  • 13:50AI applied to histopathologyFrederique Penault-Llorca
  • 14:10Dealing with new patterns of toxicityFederica Miglietta
  • 14:30The right to be forgotten: Ending Discrimination Against Cancer SurvivorsTanja Spanic

Responsabili del corso

ACCADEMIA NAZIONALE DI MEDICINA

Provider

ID Provider: N° 31

Città: Genova (GE)

Tipologia: Società, Agenzie Ed Enti Privati

Stato accreditamento: Standard - 2° Rinnovo

  • Pierfranco Conte

    Responsabile scientifico

    Specializzazione: Oncologia medica

    Struttura: Università degli Studi di Padova

    Ruolo: Professore Ordinario di Oncologia

  • Valentina Guarneri

    Responsabile scientifico

    Specializzazione: Oncologia medica

    Struttura: Istituto Oncologico Veneto / Università di Padova

    Ruolo: Professore Ordinario, Direttore Oncologia

  • Philip Poortmans

    Responsabile scientifico

    Specializzazione: Radioterapia oncologica

    Struttura: Institut Curie

    Ruolo: Head Department of Radiation Oncology

Relatori e docenti

  • Banu Arun

    Relatore

    Specializzazione: Oncologia, sindromi ereditarie BRCA

  • Bettina Borisch

    Relatore

    Specializzazione: Oncologia

  • Michele Bottosso

    Relatore

    Specializzazione: Oncologia

  • Giuseppe Curigliano

    Moderatore

    Specializzazione: Oncologia medica

  • Carmine De Angelis

    Relatore

    Specializzazione: Oncologia medica

Domande frequenti

L'evento è accreditato per: Farmacista (Farmacista Pubblico Del Ssn); Medico Chirurgo (Oncologia, Ginecologia E Ostetricia, Patologia Clinica (Laboratorio Di Analisi Chimico-Cliniche E Microbiologia)); Farmacista (Farmacista Di Altro Settore); Medico Chirurgo (Chirurgia Generale, Radiodiagnostica); Farmacista (Farmacista Territoriale); Medico Chirurgo (Radioterapia).

Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.

Sei un provider ECM?

Contattaci per scoprire come possiamo collaborare.

Contattaci